David C Schubert

US Patent:

6472436, Oct 29, 2002

Filed:

Jul 17, 2000

Appl. No.:

09/617147

Inventors:

David R. Schubert - La Jolla CA
Yuanbin Liu - San Diego CA

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

A61K 3105

US Classification:

514731, 514453, 514456

Abstract:

In accordance with the present invention, there are provided novel methods of blocking amyloid protein toxicity in cells using polycylic compounds. Also provided are novel methods of decreasing amyloid protein production in cells and methods of inhibiting cell death. Invention methods can be used to prevent and treat a diverse class of disease conditions, known as amyloidoses, which are all related to the occurrence of amyloid protein deposits. Invention methods further provide methods of identifying compounds that can block amyloid toxicity or block the amyloid protein induced inhibition of MMT reduction.

US Patent:

7053116, May 30, 2006

Filed:

Oct 11, 2002

Appl. No.:

10/269477

Inventors:

David R. Schubert - La Jolla CA, US
Yuanbin Liu - San Diego CA, US

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

A61K 31/335

US Classification:

514452, 514456, 514457, 514866

Abstract:

In accordance with the present invention, there are provided novel methods of blocking amyloid protein toxicity in cells using polycylic compounds. Also provided are novel methods of decreasing amyloid protein production in cells and methods of inhibiting cell death. Invention methods can be used to prevent and treat a diverse class of disease conditions, known as amyloidoses, which are all related to the occurrence of amyloid protein deposits. Invention methods further provide methods of identifying compounds that can block amyloid toxicity or block the amyloid protein induced inhibition of MMT reduction.

US Patent:

7531669, May 12, 2009

Filed:

Dec 30, 2005

Appl. No.:

11/323987

Inventors:

David R. Schubert - La Jolla CA, US
Yuanbin Liu - San Diego CA, US
Thomas Baiga - San Marcos CA, US

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

C07D 231/10
C07D 231/12

US Classification:

5483751, 5483761, 5483771

Abstract:

In accordance with the present invention, there are provided novel compounds that protect neurons and/or promote neuroregeneration and/or promote memory formation. Such compounds are useful for treatment of a variety of neural disorders and conditions. In another aspect of the present invention, there are also provided formulations containing one or more of the above-described compounds, optionally further containing additional neurologically active compound(s) and/or adjuvants to facilitate delivery thereof across the blood/brain barrier. In still another aspect of the present invention, there are further provided methods for treating a wide variety of neurological indications, e. g. , acute neural injuries, chronic injuries, promoting memory formation, and the like.

US Patent:

8466195, Jun 18, 2013

Filed:

Mar 15, 2010

Appl. No.:

13/255192

Inventors:

Pamela A. Maher - La Jolla CA, US
David R. Schubert - La Jolla CA, US

Assignee:

Salk Institute for Biological Studies - La Jolla CA

International Classification:

A61K 31/353

US Classification:

514456

Abstract:

Disclosed herein, inter alia, are methods and compositions for treating a complication of diabetes or a vascular disease using a 5-desoxy-flavone and/or 5-desoxy-flavonol.

US Patent:

20030077740, Apr 24, 2003

Filed:

Sep 3, 2002

Appl. No.:

10/234961

Inventors:

David Schubert - La Jolla CA, US
Atsushi Kashiwa - Yokohama, JP
Hideo Kimura - Tokyo, JP

International Classification:

C12P021/02
C12N005/06
C07H021/04
C12N009/64

US Classification:

435/069100, 435/320100, 435/226000, 435/325000, 536/023200

Abstract:

The invention provides Presenilin/Crk binding polypeptides characterized by interacting with Presenilin polypeptides, modulating intracellular calcium mobilization, and redistributing from cytoplasm to membrane in the presence of a Presenilin polypeptide. The Presenilin/Crk binding polypeptides are further characterized by interacting with a Crk polypeptide and by containing at least one SH3 domain. Also provided are isolated nucleic acids encoding Presenilin/Crk binding polypeptides, antibodies that bind to Presenilin/Crk binding polypeptides, expression vectors containing Presenilin/Crk binding polynucleotides and host cells transformed by Presenilin/Crk binding polynucleotides. The invention provides a method for identifying a compound that modulates intracellular calcium mobilization and/or modulates Presenilin/Crk binding protein levels or activity. The invention includes a method of treating a disorder associated with Presenilin/Crk binding protein. Also provided is a method of diagnosis of a subject having or at risk of having a disorder of the nervous system such as Alzheimer's disease.

US Patent:

20100305181, Dec 2, 2010

Filed:

Oct 14, 2008

Appl. No.:

12/682767

Inventors:

David R. Schubert - La Jolla CA, US

International Classification:

A61K 31/415
C07C 241/00
A61K 31/16
C07D 231/12
A61P 25/00

US Classification:

514406, 564151, 514614, 5483771

Abstract:

In accordance with the present invention, there are provided novel compounds that have a variety of properties, i.e., antioxidant, anti-inflammatory, antiviral, antibacterial, and antifungal properties. Invention compounds, therefore, have the ability to impart a variety of beneficial physiological effects, e.g., to protect neurons and/or to promote neuroregeneration and/or to promote memory formation and/or to act as protein phosphatase or kinase inhibitors and/or to act as lipoxygenase inhibitors. Such compounds are useful for treatment of a variety of indications, including neurodegenerative diseases and conditions, diabetes, ischemia associated with heart disease, and memory deficit. In another aspect of the present invention, there are also provided formulations containing one or more of the above-described compounds, optionally further containing additional neurologically active compound(s) and/or adjuvants to facilitate delivery thereof across the blood/brain barrier. In still another aspect of the present invention, there are further provided methods for treating a wide variety of neurological indications, e.g., acute neural injuries, chronic injuries, promoting memory formation, and the like.

US Patent:

52024288, Apr 13, 1993

Filed:

Sep 27, 1990

Appl. No.:

7/590359

Inventors:

David Schubert - La Jolla CA

Assignee:

The Salk Institute for Biological Studies - San Diego CA

International Classification:

C07H 1512
C07K 1300

US Classification:

4353201

Abstract:

Proteins isolated from novel clonal cell lines grown in culture are mitogenic for fibroblasts, and glial cells; some promote nerve cell survival and are prospectively useful in treating diseases such as Parkinson's and Alzheimer's which result in cell death in the nervous system, as well as in treating patients prone to epileptic seizures and patients suffering from trauma to the CNS. Certain of these proteins may be useful in nerve regeneration as well as in treating such diseases and injuries. Some are particularly useful in promoting lung development. The proteins can be topically applied in suitable compositions for wound-healing applications, and they can be administered parenterally to promote lung development and to treat patients afflicted with nerve damage and/or nerve disease.

US Patent:

55041973, Apr 2, 1996

Filed:

Mar 22, 1993

Appl. No.:

8/034245

Inventors:

David R. Schubert - La Jolla CA
Wolfgang H. Fischer - Encinitas CA

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

C07H 2104
C12N 1512
C12N 1511
C12N 1500

US Classification:

536 235

Abstract:

Neurotrophic growth factor proteins isolated from novel clonal cell lines grown in culture are mitogenic for fibroblasts and glial cells; some promote nerve cell survival and are prospectively useful in treating diseases such as Parkinson's and Alzheimer's which result in cell death in the nervous system, as well as in treating patients prone to epileptic seizures and patients suffering from trauma to the CNS. Certain of these proteins may be useful in nerve regeneration as well as in treating such diseases and injuries. Some are particularly useful in promoting lung development. These proteins are also useful in methods of treating a patient to promote nerve cell regeneration in degenerative eye diseases. The proteins can be topically applied in suitable compositions for wound-healing applications, and they can be administered parenterally to promote lung development and to treat patients afflicted with nerve damage and/or nerve disease.